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Since the identification of the receptor for advanced glycosylation end products (RAGE) in 1992, there have been tremendous strides made in
our understanding of the role RAGE receptors play in a variety of physiological and pathological processes. Despite such progress, several
fundamental aspects of RAGE expression and RAGE function remain largely unanswered. In particular, while multiple forms of the RAGE
receptor are known to exist, little is known with regards to how these different isoforms of the RAGE receptor work together to mediate RAGE
signaling. For example, some forms of the RAGE receptor may promote deleterious feed-forward pathways, while others may serve to inhibit
deleterious activation of the RAGE receptor. Additionally, important questions remain with regards to the intracellular domain of the full-length
RAGE receptor, and the specifics surrounding how intracellular signaling pathways become activated via the RAGE family of receptors. The
focus of this review is to address each of these important issues, as well as other key aspects of RAGE biology, and discuss how they are important
for both our understanding of the physiological and pathological roles of RAGE signaling within the brain.
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In attempting to identify the presence of receptors for
glycated proteins in the bovine lung, investigators described
the presence of a high affinity receptor present on the cell
surface. This receptor was subsequently purified and defined as
the full-length receptor for advanced glycosylation end
products (RAGE). Upon sequencing, the RAGE receptor was
characterized as being a member of the immunoglobulin
superfamily [1–4], and was observed to display a high degree
of structural and sequence homology to the neural adhesion
molecules (N-CAM). Structurally, each of the principle iso-
forms of the RAGE receptor contains an N-terminal V-type
domain followed by 2 C-type domains (Fig. 1). The V-type
domain is believed to be the principle site for ligand binding,
although the C-type domains likely play a key role in
stabilizing the V-domain for ligand interactions. RAGE is a
multiligand receptor, which binds a diverse range of molecules,
with a preference for ligands that are prone to aggregation and0167-4889/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
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The full-length form RAGE has a single transmembrane
domain that contains a 43 amino acid intracellular domain
(Fig. 1). This short cytoplasmic tail of the full-length RAGE
receptor has no known phosphorylation sites, G-protein
binding sites, or kinase binding sites. Regardless, the cytoplas-
mic tail is absolutely essential for the intracellular signaling.
2. RAGE isoforms
When discussing RAGE, it is important to keep in mind
that there are at least 3 major forms of RAGE. These different
RAGE isoforms are generated as the result of alternative
splicing and can loosely be defined as being the full-length
RAGE, dominant negative RAGE (DNRAGE), and secretory
RAGE (sRAGE) (Fig. 1). Each of these forms of RAGE
contain the V-type and C-type domains, and are presumably
able to bind RAGE ligands with similar affinity (Fig. 1),
although this remains to be fully elucidated experimentally.
Each of these forms of the RAGE isoforms is generated as the
result of splicing from a single RAGE gene, although some
differential forms of RAGE in mice may result as the result of
protein cleavage instead of splicing [5]. It is important to keepta 1746 (2005) 18 – 27
http://www
Fig. 1. There are multiple isoforms of the RAGE receptor. The 3 dominant isoforms of the RAGE receptor are known as full-length RAGE, soluble RAGE (sRAGE),
and dominant negative RAGE (dnRAGE). Each of these receptors contains a V-type domain and 2-C type domains for ligand binding, but each RAGE isoform
differs considerably in cellular function. The sRAGE receptor is released from the cell and allowed to interact with RAGE ligands prior to their interacting at the
plasma membrane. The dnRAGE lacks the intracellular signaling domain, and therefore binds RAGE ligands without directly transducing a signal. Together, the
presence of these 3 main isoforms of RAGE suggests that the ability of any RAGE ligand to induce RAGE signaling depends on the coordinated effects of the
different RAGE receptors. At least 3 additional forms of RAGE are found in the human brain (RAGEb, sRAGEb, dnRAGEb), arrows indicate the areas of each
brain isoform that is unique.
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isoforms in mice remains controversial, with recent studies
from our laboratory confirming the possibility of RAGE
splicing in the mouse brain (J.N. Keller, unpublished
observations). It is interesting to note that splicing variants
for of each of the 3 well established RAGE isoforms are also
known to exist [6–11]. In particular, studies from our
laboratory have identified the presence of at least 3 novel
forms of RAGE in the human brain [9]. These specialized
forms of RAGE may be particularly important to a variety of
pathological conditions [6–11], and are discussed in more
detail below. Additionally, polymorphisms in RAGE are also
known to exist, with polymorphisms profoundly affecting the
function of RAGE [12–14]. In order to develop an accurate
understanding of RAGE signaling in the brain and central
nervous system (CNS), it is important to understand the
interaction, expression, and function of each of these RAGE
isoforms.
2.1. Full-length RAGE
Full-length RAGE is by far the most studied of the 3 major
forms of RAGE, with numerous studies identifying a role for
full-length RAGE as a direct mediator of physiological as well
as pathological responses [1–4]. The full-length form of
RAGE contains a single transmembrane region, followed by
a short intracellular domain (Fig. 1). The intracellular domain
of RAGE is necessary for many forms of RAGE signaling,
including the activation of nuclear factor k-B (NF-kB), mitogen
activated protein kinase (MAPK), and Jun-N-terminal kinase
(JUNK) [15–20]. Interestingly, the activation of these different
pathways by full-length RAGE may involve members of theRho-family of GTPases as well as RAS [1–4,15–20]. At the
present time, it is assumed that the intracellular domain of the
full-length RAGE receptor serves as a scaffolding for the
initiation of signal transduction. For example, a recent report
suggests that a D-domain on the cytoplasmic tail of RAGE may
provide for direct docking of MAP kinase to the cytoplasmic
domain of full-length RAGE [21]. However, it is important to
point out that these studies were conducted using robust
expression of only the intracellular domain of RAGE for
binding analysis. As such, these data may not accurately reflect
what occurs with the actual full-length RAGE receptor. A
number of RAGE ligands, as well as RAGE activation itself,
can induce oxidative stress. Because reactive oxygen species
(ROS) are sufficient to stimulate signal transduction, it is
critical to elucidate how ROS might be involved in RAGE
signaling. For example, it will be important to determine if
there are ROS-dependent as well as ROS-independent modes
of RAGE signaling. Additionally, studies need to elucidate the
role of the intracellular domain in these potentially different
modes of signal transduction. While studies with antioxidants
have demonstrated a necessity for ROS in some forms of
RAGE-induced signal transduction [22,23], they have not
provided an overview as to how antioxidants affect the other
established RAGE signaling pathways. Indeed, most studies
have focused on the ability of antioxidants to prevent or
ameliorate the activation of NF-kB in response to RAGE
activation, with little known about the role of ROS in other
downstream signaling pathways. Additionally, it is unclear
whether ROS are a general mediator of RAGE signaling, or
whether certain RAGE ligands may have a higher dependence
upon ROS generation for the initiation of downstream path-
ways. As mentioned previously, at present, the proteins which
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well as unstimulated conditions, have not been identified.
Identifying such proteins is absolutely paramount to under-
standing RAGE induced signal transduction for both physio-
logical as well as pathological conditions. It will also be
important to identify the role of ROS as a potential regulator of
these different proteins which may bind to the intracellular
domain of full-length RAGE.
Signaling through full-length RAGE is known to be vital for
a number of physiological as well as pathological processes.
These include chemotaxis, angiogenesis, inflammation, neurite
outgrowth, apoptosis, and proliferation [1–4]. It is extremely
interesting that the same receptor–ligand interaction can have
such varied and cell type-specific effects. Presumably the
ability of RAGE activation to induce these varied responses is
due at least in part to the fact that a given signal transduction
pathway can have extremely cell type specific effects. For
example, it is well established that the activation of NF-kB is
absolutely essential for viability in some cells, and induces
apoptotic pathways in other cells [24]. In most paradigms, it
has been determined that one of the most rapid effects of
RAGE activation is the generation of more full-length RAGE
on the cell surface. The presence of more full-length RAGE
presumably results in greater and more sustained signaling
through the full-length RAGE receptor. In this scenario, once
full-length RAGE becomes activated, its signaling is rapidly
accelerated and potentially difficult to ameliorate. Because
sRAGE and DNRAGE are both able to suppress signaling
through the full-length RAGE receptor, it is likely that one ofFig. 2. Interplay between the different RAGE isoforms. Beta amyloid (Ah) can form
Ah is soluble, while oligomeric and crosslinked Ah displays increasing levels of
RAGE (sRAGE) can ameliorate the progression of Ah insolubility, and thereby decre
Ah before it encounters the plasma membrane, and thereby attenuate intracellula
(dnRAGE), which lacks the intracellular domain, can bind Ah and thereby prevent
serve to ameliorate RAGE signaling. Presumably, this same model holds for other R
yellow ovals indicate the presence of post translational modifications such as oxidatheir main functions is to serve as vital inhibitors of full-length
RAGE activation.
2.2. Soluble RAGE
The soluble form of RAGE contains the same V-type and C-
type regions found on the other isoforms of RAGE (full-length
RAGE, DNRAGE), but lacks the transmembrane domain (Fig.
1). As a result, sRAGE is released into the extracellular space
and allowed to interact with RAGE ligands prior to their
potential binding to full-length RAGE (Fig. 2). As a result,
sRAGE is presumably able to suppress the activation and
signaling of full-length RAGE, by sequestering the RAGE
ligands prior to their interaction with the full-length RAGE
receptor. An alternative mechanism by which sRAGE can
modulate signaling full-length RAGE is by altering the
generation and maturation of potential RAGE ligands. This is
perhaps best illustrated in the analysis of sRAGE and beta
amyloid (Ah). It is well established that Ah (a small peptide of
40–42 amino acids) undergoes increasing degrees of aggrega-
tion, which is associated with fibrillization and oligomerization
[25,26]. As the aggregation of Ah increases, it begins to form
higher ordered structures, ultimately generating highly cross-
linked and insoluble plaques (Fig. 2). The different forms of
Ah (soluble/insoluble) are known ligands for full-length
RAGE (Fig. 2), with signaling through RAGE believed to
play a potentially important role in the Ah pathogenesis
observed in Alzheimer’s disease (AD) [27–33]. It is important
to keep in mind that in this model full-length RAGE is believedhigher ordered complexes that increase beta amyloid insolubility. Monomeric
insolubility, ultimately generating highly insoluble and stable plaques. Soluble
ase the generation of RAGE ligands. Soluble RAGE can also bind to oligomeric
r RAGE signaling. Additionally, the expression of dominant negative RAGE
direct RAGE signaling. This model indicates that at least 2 forms of RAGE can
AGE ligands (oxidized LDL, advanced glycosylation end products, etc.). *The
tion and glycosylation.
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not be stimulated to the same degree in response to monomeric
and soluble Ah (Fig. 2). Recent studies indicate the soluble
forms of RAGE are able to not only bind Ah in the earliest
stages of aggregation, but also demonstrate that the binding of
soluble RAGE to Ah dramatically ameliorates Ah aggregation
and prevents the generation of insoluble Ah structures (Fig. 2)
[34]. As a result, soluble RAGE is able to suppress full-length
RAGE activation by sequestering RAGE ligands before they
encounter the membrane form of RAGE, and also by
decreasing the generation of RAGE ligands (Fig. 2). In future
studies, it will be important to elucidate the ability of sRAGE
to prevent other potential RAGE ligands from initially forming.
Additional evidence in a variety of transgenic mouse models
suggest that sRAGE has important inhibitory effects on full-
length RAGE signaling. For example, administration of soluble
RAGE into the circulatory system has been demonstrated to
suppress atherosclerosis, atherogenesis, increase wound heal-
ing, and increase peripheral nerve regeneration [1–4,35–37].
Presumably, in each of these models, sRAGE serves to
ameliorate the activation of full-length RAGE by preventing
the interaction of RAGE ligands with the full-length form of
the receptor. Additionally, we propose that the beneficial
effects of sRAGE may be manifest by ameliorating the
generation of RAGE ligands (similar to what occurs with
Ah). For example, the oxidation of low density lipoprotein
molecules or the generation of AGE-modified proteins
increases their propensity to aggregate or form higher order
complexes. The presence of sRAGE may play a role in
ameliorating such aggregation and thereby prevent the forma-
tion of potentially more efficacious activators of RAGE
signaling. Consistent with such a scenario, infusion of sRAGE
into the circulatory system decreases the binding of AGE
modified proteins to the endothelial cell surface [38]. Indeed, at
the time of this publication, a host of new reports describing
alterations in the levels of circulating sRAGE correlating with
the onset or severity of pathogenesis have strengthened the
importance of sRAGE to a wide variety of disorders [39,40].
A newly published report suggests that the greatest
expression of sRAGE in the brain is localized to neuronal
cytoplasm [41]. Studies from our laboratory have demonstrat-
ed that at least 2 forms of sRAGE (nearly identical) are
expressed in the human brain, with sRAGE mRNA observed
to be at least 3 fold higher than other forms of RAGE [9].
Such findings suggest that healthy neurons may retain a
healthy reserve of sRAGE to release upon encountering
potentially stressful stimuli such as AGEs or Ah. Together,
these data highlight the importance of RAGE activation to a
number of pathogenic processes, and highlight the potential
therapeutic role for sRAGE in these different pathogenic
conditions. Recent studies have demonstrated the ability of
sRAGE administration to the circulatory system of rodents is
able to prevent beta amyloid from the circulatory system from
crossing into the brain [42] and ameliorate the formation of
diffuse plaques [43]. Despite such reports, one can make the
case that relatively little is known experimentally about the
potential for sRAGE as an ameliorator of Ah pathogenesis invivo. For example, does sRAGE suppress the formation and
toxicity of soluble and insoluble oligomeric forms of Ah? Is
sRAGE able prevent the formation of neuritic plaques, or is it
only capable of suppressing diffuse plaque formation?
Similarly, it is unclear whether the ability of sRAGE to
suppress plaque formation requires that it be present in the
circulatory system or whether sRAGE mediates its effects
directly in the brain?
2.3. Dominant negative RAGE
The least characterized and understood of the RAGE
isoforms is the DNRAGE. This form of RAGE is identical to
full-length RAGE, only lacking the short intracellular domain
of full-length RAGE (Fig. 1). Presumably, this form of RAGE
competes for the binding of RAGE ligands and prevents the
activation of full-length RAGE due to its lack of an
intracellular domain (Fig. 2). The majority of our understand-
ing of this form of the RAGE receptor has come from
transfection studies, which demonstrated that dramatic upre-
gulation of DNRAGE decreases full-length RAGE activation
[27,29]. However, it is important to note that these studies were
short-term studies (less than 48 h) and may not provide an
accurate representation of the in vivo paradigm. For example, a
number RAGE ligands are deleterious to most cell types
(AGEs, oxidized lipoproteins, Ah, etc.), and binding of these
ligands to DNRAGE would be expected to hold them at the cell
surface. While holding of such ligands at the cell surface and
preventing their initial binding to full-length RAGE may be
beneficial during the initial periods of ligand binding, the long-
term effects may be less advantageous. For example, one could
imaging that the localization of these ligands at the cell surface
may allow for the initiation of further ligand recruitment,
oxidation, and aggregation. This may be particularly true for
Ah and oxidized lipoproteins, which then promote the
activation of full-length RAGE. However, experimentation is
needed to clarify the validity of this hypothesis. In a recent
report, we have demonstrated that the level of DNRAGE
expression in the human brain is similar to full-length RAGE
[9]. However, little is currently known about how the ratio of
full-length RAGE and DNRAGE is altered in response to
physiological and pathological stimuli. Such data may be
important in identifying a role for DNRAGE as a suppressor of
full-length RAGE signaling.
2.4. Additional splice variants of RAGE
While there are 3 predominant forms of RAGE, a growing
number of studies have highlighted the presence of additional
RAGE splice variants [6–11]. For example, alternatively
spliced forms of sRAGE and full-length RAGE have been
reported [6–11]. Interestingly, three of these studies demon-
strated evidence of alternative RAGE splicing in brain
astrocytes [7], neural cells [8], and human brain tissue [9].
These alternative splicing events result in the truncation of
exons as well as the failure to remove intronic sequences from
RAGE mRNA. It is highly likely that the protein products
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that is highly specialized. The potential importance and
interest in these various splice variants is growing in light
of the fact they appear to be cell type specific, and may be
linked with specific pathological conditions [7,11]. In a recent
study, we have demonstrated evidence for at least 3 novel
forms of RAGE in the human brain (Fig. 1) [9]. Elucidating
the presence of these variants at the protein level, and
identifying their unique properties, appear to be a particularly
important area of future studies into RAGE signaling. In
particular, it will be important to determine the role of these
different RAGE variants may have in age-related disorders of
the CNS, including AD.
2.5. Polymorphisms in RAGE
Another rapidly growing area of RAGE research indicates a
role for polymorphisms in RAGE as mediators of altered
RAGE function. Additional reports have linked RAGE poly-
morphisms with multiple pathological conditions. For example,
a number of studies have now identified the presence (and
potential linkage) of a G82S polymorphism in RAGE to both
rheumatoid arthritis and diabetes [12–14]. The G82S poly-
morphism is located within the V-type immunoglobulin
domain of RAGE and appears to slightly increase the binding
of RAGE ligands to the surface of Chinese hamster ovary cells,
and dramatically elevate the activation of inflammatory
signaling pathways [14]. It has therefore been speculated that
the presence of RAGE polymorphisms may shift RAGE
signaling to being more pathological in nature, with elevated
inflammation and oxidative stress from RAGE activation
contributing to the induction of diabetes and rheumatoid
arthritis. It is unclear whether polymorphisms in RAGE
potentially contribute to alterations in brain homeostasis,
although it is enticing to speculate on the presence of RAGE
polymorphisms contributing to alterations in oxidative stress
and inflammatory signaling in the brain, and potentially
contributing to the development of age-related disorders of
the CNS.
3. RAGE ligands
A large number of ligands for RAGE have been identified in
the brain as well as other tissues. A number of studies have
demonstrated that advanced glycosylation end product (AGE),
S100/calgranulins, Ah, and amphoterin are all natural ligands
for RAGE [1–4,44]. Although numerous studies have ana-
lyzed the ability of these different ligands to stimulate RAGE,
currently very little is known about the contribution these
different ligands play in mediating RAGE signaling within the
CNS. Additionally, little is known about the potential
synergistic or inhibitory effects of the different RAGE ligands
on the RAGE-mediated signaling. Understanding more of the
specifics that currently surround the effects of these different
ligands, and elucidating their potential interactions with one
another, is clearly much needed to accurately understand
RAGE signaling in the brain.3.1. Advanced glycosylation end products (AGEs)
AGEs are formed from a series of glycosylation and
oxidation reactions with sugars and amino acids, with the
amino acid side chains of lysine, histidine, and arginine
particularly vulnerable to modification by AGEs [1–4,45–
47]. The most common sugars for AGE formation include
glucose, fructose, and triose-phosphates. Each of these sugars
form a Schiff base adduct that is modified to a ketoamine
Amadori product. This reaction is referred to as non-enzymatic
glycosylation or the Malliard reaction, and generates reversible
glycosylation. Once exposed to oxidation reactions, these
glycosylation events form fluorescent products that are then
defined as being AGEs. These AGEs form irreversible
modifications to proteins, which render proteins resistant to
protease digestion and elevate protein crosslinking. Interest-
ingly, AGEs have been demonstrated to accumulate in the
intracellular as well as extracellular space as a part of normal
brain aging [47]. Age-related disorders such as AD demon-
strate an exacerbation of AGEs as compared to age-matched
controls, with AGEs associated with numerous pathological
features of the AD brain. Interestingly, there is a strong
association between Ah deposition and AGEs in the brain [45].
This may be particularly important given the fact that Ah and
AGEs are both ligands for RAGE, and may therefore promote a
synergistic activation of RAGE. Evidence for potential synergy
is highlighted by the fact that AGEs are capable of accelerating
the nucleation-dependent polymerization of Ah [45].
Interactions between AGEs and the various RAGE isoforms
have been well documented outside of the CNS. For example,
studies have demonstrated that AGEs interact with full-length
RAGE and sRAGE in tissues of the vasculature [1–4,45–47].
Additionally, studies have demonstrated that many effects of
AGE administration require the presence of the cytoplasmic tail
of full-length RAGE [1–4,45,48]. Together, these studies
suggest that sRAGE and DNRAGE likely play key roles in
inhibiting signaling mediated by the interaction of AGEs with
full-length RAGE [1–4,45,48]. Because such signaling can
induce a diverse array of physiological responses, ranging from
proliferation to apoptosis, it is likely that AGE-RAGE
interactions are important to brain aging and age-related
diseases of the CNS. However, at the present time little is
known about the role and effects of AGEs in physiological or
pathological responses observed in the brain.
3.2. S100/calgranulins
The S100/calgranulin proteins are closely related, and have
been best characterized for their role in intracellular calcium
binding [1–4,49–52]. However, in addition to binding calcium
these proteins also have an established role in protein export
[50,51]. Once outside of the cell, members of the S100/
calgranulin family of proteins can potently bind to the different
RAGE isoforms. Members of the S100/calgranulin protein are
highly expressed throughout the brain and CNS, with
expression localized predominantly to astrocytes and specific
neuron populations [49–52]. The binding of S100/calgranulins
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outgrowth and neuron survival in a variety of in vitro studies
[49–52]. Additionally, S100/calgranulin proteins have been
demonstrated to have multiple effects on microglia including
the stimulation of nitric oxide release as well as the activation
of multiple signal transduction pathways [53,54]. Interestingly,
it appears that in some models the activation of NFkB, which is
RAGE dependent [53,54], can be separated from other S100-
induced events such as nitric oxide release. The concentration
of S100/calgranulin within the extracellular space appears to be
a particularly important factor in predicting its overall effect on
cellular homeostasis, with low concentrations driving more
beneficial events (neurite outgrowth), and high concentrations
inducing more deleterious events (inflammatory signaling). In
future studies, it will be important to elucidate the relative
contribution of differential RAGE activation to this dose-
dependent variability in S100/calgranulin mediated signaling.
For example, it will be important to elucidate whether low
concentrations of S100/calgranulin may selectively bind to a
specific RAGE variant.
3.3. Amphoterin
Amphoterins are members of the high mobility group 1
(HMG-1) nonhistone chromosomal DNA binding proteins
[52,55], which have been demonstrated to potently induce
inflammatory signaling in the CNS as well as non-CNS tissues
[52,55–57]. In general, the term amphoterin is generally
reserved for the membrane bound forms of HMG-1 protein,
although this term is used loosely in the literature. The
members of the amphoterin/HMG-1 group of proteins are
expressed at their highest levels in the CNS during embryonic
development [52,55–57], although they may be significantly
elevated within the CNS in response to injury [52,55–57]. The
ability of amphoterin/HMG-1 proteins to induce inflammatory
responses can be RAGE dependent, as well as RAGE
independent, contributing to the complexity surrounding the
effects of this RAGE ligand. Similar to S100/calgranulin
proteins, amphoterin is also a potent inducer of neurite
outgrowth [49,55–57]. It is important to note that there is a
tremendous overlap between neuronal RAGE expression and
the neuronal expression of amphoterin, during the development
of the CNS. Taken in conjunction with the ability of
amphoterin/HMG-1 proteins to induce neurite outgrowth,
numerous investigators have suggested an important physio-
logical role for amphoterin/HMG-1 signaling through RAGE
during neuronal development. It appears that amphoterin/
HMG-1 signaling through RAGE can therefore have both
beneficial as well as potentially deleterious effects upon
cellular homeostasis. Additionally, it appears that the ability
of the same stimuli (amphoterin/HMG-1) to induce divergent
responses is due to the cell type specific nature of RAGE
signaling. For example, in neurons, the binding of amphoterin
complexes results in beneficial neurite outgrowth, while in
microglia that same ligand induces potentially deleterious
increases in inflammatory signaling. Such data raise the
possibility that expression of the different RAGE isoformsmay be altered at the cell surface in a cell type specific manner,
and account for the dramatic differences in outcome following
exposure to the same RAGE ligand.
3.4. Beta amyloid
Ah is believed to play an important role in promoting
increased oxidative stress and mediating the increased neuron
death observed in the AD brain [25–27]. Ah is a peptide
fragment, principally 40 or 42 amino acids in length that is
generated as the direct result of proteolytic cleavage from the
h-amyloid precursor protein (APP) [25,26]. Increased levels of
Ah are observed in AD, and are increased by a gradual and
progressive increase in the steady-state levels of Ah as the
result of altered Ah synthesis and decreased catabolism of Ah
[25,26]. As mentioned previously, once generated, Ah is
capable of generating complexes with increasingly complicated
structure (Fig. 3).
A number of studies have identified that RAGE receptors
bind beta amyloid, binding monomeric, fibrilized and presum-
ably oligomerized Ah (Fig. 2). RAGE immunoreactivity has
also been demonstrated at the sites of Ah deposition [27–32].
Additionally, RAGE has been suggested to be a principle
receptor for binding Ah at the cell surface [28–30]. The
binding of Ah to the cell surface has also been suggested to
increase Ah aggregation at the plasma membrane. Together,
these studies have suggested that Ah signaling through RAGE
is responsible for a significant amount of Ah induced oxidative
stress, inflammation and neurotoxicity [27–32]. However, it is
important to point out that these previous studies have
excluded the potential role of sRAGE and DNRAGE to these
previous findings. For example, it is unclear whether the
RAGE immunoreactivity at the site of Ah deposition is full-
length membrane bound RAGE, DNRAGE, or represents the
binding of sRAGE. The binding of sRAGE to these Ah
deposits could indicate an attempt to inhibit further Ah
deposition, or serve as a means of preventing the binding of
Ah to the full-length RAGE receptor. A recent study has
demonstrated the ability of sRAGE to not only bind Ah, but
also prevent its aggregation and its ability to form higher order
complexes [34]. As such, the ability of sRAGE to bind Ah may
dramatically interfere with the ability of Ah to bind to
membrane bound RAGE and directly transduce potentially
toxic signal transduction. Additionally, the potential role of
endogenous DNRAGE in decreasing Ah signal transduction is
poorly understood. It is likely that the expression of sRAGE
and DNRAGE dramatically increases in response to elevating
levels of Ah, and suggest that increased levels of sRAGE or
DNRAGE could potentially serve as a potential therapeutic
target for successfully suppressing Ah toxicity. It will be
important to elucidate the contribution of alterations in the ratio
of sRAGE/DNRAGE/RAGE and Ah as a potential trigger for
the initiation of Ah toxicity in AD.
In AD, it has been reported that there is an increased level of
circulating IgGs which bind RAGE peptides [58]. Interestingly,
there appeared to be a cross reactivity with IgGs which
recognize Ah peptides and RAGE peptides, suggesting that the
Fig. 3. The effect of RAGE activation is mediated by the combined levels of the different RAGE ligands, and cell type specific effects of RAGE activation. Multiple
ligands for RAGE exist within the CNS including HMG-1, S100, AGEs, and beta amyloid (Ah). The ability of these different ligands to interact with cell surface
RAGE receptors is controlled by numerous inhibitory factors, the most important of which is likely to be sRAGE. Once the different ligands interact with the RAGE
receptors at the cell surface, they elicit cell type specific effects. The effects of RAGE activation on neuronal, astrocyte, and microglia populations diverges based on
the levels of RAGE, and the specific RAGE isoforms, present on the cell surface.
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complex. It is important to point out that the increase in
circulating RAGE IgGs were demonstrated to not occur as the
result of a linkage between diabetes and AD [58]. When mice
were immunized with an AGE-modified protein, the mice
generated IgGs against the RAGE receptor and Ah [59]. These
studies provide an additional linkage between circulating levels
of anti-RAGE and anti-Ah IgGs. Such linkages have caused
some investigators to speculate that anti-RAGE IgGs may have
both diagnostic as well as therapeutic potential in AD. It will be
important in future studies to address the mechanisms
responsible for the linkage between the levels of anti-RAGE
and anti-Ah IgGs in AD subjects. Additionally, studies are
needed to elucidate the potential function, or effects of
circulating RAGE, with the function of RAGE within the brain.
4. Coordinated signaling through RAGE
Based on the large number of RAGE isoforms, the presence
of additional splice variants for each of these RAGE isoforms,
and the presence of RAGE polymorphisms, it is clear that when
one speaks of RAGE signaling one is referring to an outcome
that is the result of the interplay between all of these different
factors. In the first set of factors, one has to consider the
relative amounts of the different RAGE ligands which are
present within a specific area of the brain (Fig. 3). In
conducting such analysis it is important to not only measure
the amount of the individual RAGE ligands which are present,
but also begin to elucidate the very real possibility that these
ligands may have synergistic or inhibitory effects towards one
another (Fig. 3). The effects of these different ligands onRAGE signaling is regulated, at least in part, by the ability of
sRAGE to bind the ligand prior to reaching the full-length
RAGE receptor (Fig. 3). By increasing or decreasing the ability
of sRAGE to interact with these different RAGE ligands, it is
likely that sRAGE serves as a direct and profound modulator in
determining the amount of ligand which encounters RAGE
receptors on the cell surface. Once the RAGE ligands
encounter the cell surface of CNS cells, there will likely be
some shared responses, but the ultimate effect on cellular
homeostasis is likely to be cell type specific (Fig. 3). For
example, Ah signaling through RAGE in a microglia is likely
to increase oxidative burst and proliferation, while the same
ligand–receptor interaction in a neuron is likely to promote
apoptosis (Fig. 3). Evidence also suggests that under conditions
of high level RAGE expression at the cell surface, RAGE
activation may induce growth arrest and even apoptosis in
microglia [43,49,60,61]. Accurately understanding and target-
ing of RAGE signaling in potential therapies will clearly rely
on the utilization of models which take into account each of
these complexities that currently cloud our understanding of
RAGE in the CNS.
Because the vast majority of previous studies have
discussed RAGE in terms of being one receptor, considerable
confusion has emerged in this growing field. It is important to
note that some potentially important assumptions have also
been made in previous studies. For example, the vast majority
of immunohistochemical studies have used antibodies which
are not capable of distinguishing between the different RAGE
isoforms. As a result, it is unclear if immunostaining represents
the expression of sRAGE, DNRAGE or full-length RAGE. As
outlined above, such identification and characterization is
Q. Ding, J.N. Keller / Biochimica et Biophysica Acta 1746 (2005) 18–27 25critical to accurately interpreting experimental results, as each
of these forms of RAGE can have dramatically different effects
on cellular function.
It is vital to understand the overall balance of RAGE
expression in physiological and pathological conditions, as it is
likely that subtle shifts in the ratio of full-length RAGE and the
amount of inhibitory forms of RAGE, significantly impacts
intracellular signaling. Furthermore, the potential loss of
inhibitory forms of RAGE (sRAGE, DNRAGE) in the CNS
has never seriously been addressed in previous immunohisto-
chemical studies, thus findings from these previous studies
may have inadvertently added confusion to our understanding
of how RAGE expression is altered in both physiological as
well as pathological settings within the CNS. Clarification of
the expression of all RAGE receptor isoforms, as well as any
potential polymorphisms, is therefore desperately needed in
both the physiological as well as pathological setting.
Additionally, future studies need to critically evaluate what
role RAGE signaling plays in the both the development of the
CNS, as well as the inflammation and neurodegeneration
evident in the various CNS disorders such as AD.
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